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ABSTRACT Due to the spread of resistance, antibiotic exposure receives increasing attention. Ecological consequences for the
different niches of individual microbiomes are, however, largely ignored. Here, we report the effects of widely used antibiotics
(clindamycin, ciprofloxacin, amoxicillin, andminocycline) with different modes of action on the ecology of both the gut and the
oral microbiomes in 66 healthy adults from the United Kingdom and Sweden in a two-center randomized placebo-controlled
clinical trial. Feces and saliva were collected at baseline, immediately after exposure, and 1, 2, 4, and 12 months after administra-
tion of antibiotics or placebo. Sequences of 16S rRNA gene amplicons from all samples andmetagenomic shotgun sequences
from selected baseline and post-antibiotic-treatment sample pairs were analyzed. Additionally, metagenomic predictions based
on 16S rRNA gene amplicon data were performed using PICRUSt. The salivary microbiome was found to be significantly more
robust, whereas the antibiotics negatively affected the fecal microbiome: in particular, health-associated butyrate-producing
species became strongly underrepresented. Additionally, exposure to different antibiotics enriched genes associated with antibi-
otic resistance. In conclusion, healthy individuals, exposed to a single antibiotic treatment, undergo considerable microbial
shifts and enrichment in antibiotic resistance in their feces, while their salivary microbiome composition remains unexpectedly
stable. The health-related consequences for the gut microbiome should increase the awareness of the individual risks involved
with antibiotic use, especially in a (diseased) population with an already dysregulated microbiome. On the other hand, under-
standing the mechanisms behind the resilience of the oral microbiome toward ecological collapse might prove useful in combat-
ing microbial dysbiosis elsewhere in the body.
IMPORTANCE Many health care professionals use antibiotic prophylaxis strategies to prevent infection after surgery. This prac-
tice is under debate since it enhances the spread of antibiotic resistance. Another important reason to avoid nonessential use of
antibiotics, the impact on our microbiome, has hardly received attention. In this study, we assessed the impact of antibiotics on
the humanmicrobial ecology at two niches. We followed the oral and gut microbiomes in 66 individuals from before, immedi-
ately after, and up to 12 months after exposure to different antibiotic classes. The salivary microbiome recovered quickly and
was surprisingly robust toward antibiotic-induced disturbance. The fecal microbiome was severely affected by most antibiotics:
for months, health-associated butyrate-producing species became strongly underrepresented. Additionally, there was an enrich-
ment of genes associated with antibiotic resistance. Clearly, even a single antibiotic treatment in healthy individuals contributes
to the risk of resistance development and leads to long-lasting detrimental shifts in the gut microbiome.
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Health care in the 21st century is seriously challenged by theincreasing prevalence of bacteria that are resistant to antibi-
otics. Excessive and incorrect use of antibiotics results in the emer-
gence of both specific-drug-resistant andmultidrug-resistant bac-
terial strains (1), also known as “superbugs.” The occurrence of
superbugs is associated with treatment failure, higher morbidity
and mortality, and increased health care costs (2). In addition to
the emergence of antibiotic-resistant strains, the use of antibiotics
is associated with an altered and often less diverse composition of
the gut microbiome (3, 4) and with the increased prevalence of
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ectopic diseases such as asthma, eczema, and inflammatory bowel
disease (5–8).
Alarmingly, the use of antibiotics without evidence-based ben-
efit for the patient is widespread. In developing countries, lack of
governmental control, low costs, and over-the-counter availabil-
ity have led to a sharp rise in self-medication with antibiotics (9),
where even common cold symptoms such as sore throat and head-
ache are self-treated with antibiotics such as amoxicillin, tetracy-
cline, and ciprofloxacin (10). In developed countries, antibiotics
are frequently prescribed before surgery as a prophylacticmeasure
for preventing infection. For instance, in the United Kingdom,
one of the highest rates of antibiotic prescriptions in the outpa-
tient population comes from dentists and oral surgeons (11, 12).
Systemic antibiotics are commonly prescribed before removal of
the third molar (wisdom tooth), periodontal therapy, placement
of dental implants, or other surgery in the oral cavity. Although
the clinical benefits of these measures are highly debated (13–15),
they still form a common practice.
So far, studies that have assessed the ecological impact of anti-
biotics on the human microbiome are scarce and have focused
only on the gut (16–18). Potential negative effects of prophylactic
antibiotic use on the oral microbiome have been entirely ne-
glected. Another important aspect that has not been investigated is
the impact of systemically administered antibiotics on the micro-
biome at different niches within an individual. There might be
significant collateral damage, for instance, to the gut microbiome
due to unnecessary and clinically ineffective preventive antibiotic
use before standard oral surgery.
In order to elucidate the impact of systemic antibiotics simul-
taneously on the oral and the gut microbiome ecology within the
same individual, we performed two randomized placebo-
controlled clinical trials with four widely used antibiotics. These
included four different antibiotic classes with different modes of
action, antimicrobial spectra, and pharmacokinetic properties—a
lincosamide (clindamycin), a quinolone (ciprofloxacin), a tetra-
cycline (minocycline), and a penicillin (amoxicillin). Lincos-
amides inhibit bacterial protein synthesis by binding to the 50S
ribosomal subunit and hence ultimately inhibit microbial growth
(19). The lincosamide clindamycin has a broad spectrum of anti-
microbial activity, including Gram-positive aerobes and anaer-
obes, Gram-negative anaerobes, and selected protozoa and fungi
(20). Quinolones are broad-spectrum bactericidal agents active
against many Gram-positive and Gram-negative bacteria; they
target the bacterial enzymes DNA gyrase andDNA topoisomerase
(21), both essential in DNA replication and repair. Tetracyclines
bind to the 30S ribosomal subunit and act by inhibiting protein
synthesis after uptake into susceptible organisms by active trans-
port and are bacteriostatic rather than bactericidal (22). Finally,
the penicillin-type antibiotic amoxicillin is a broad-spectrum
beta-lactam antibiotic that interferes with synthesis of the bacte-
rial cell wall peptidoglycan (22).
Our study involved two clinical sites—the Swedish site (Karo-
linska Institute [KI]) with 30 individuals and theUnited Kingdom
site (Helperby [HP]) with 44 individuals. In either site, subjects
were randomized into a group receiving a placebo treatment and
into two groups that received orally administered antibiotics. In
theKI study, data fromwhichmajor genera and species richness in
the intestinal samples were reported previously (18), the antibiot-
ics used were ciprofloxacin or clindamycin, while in the HP study,
subjects received either minocycline or amoxicillin. We analyzed
the salivary and fecal microbiomes of healthy adults before and
after a standard antibiotic administration at various time points
during 1 year. As a reference, we compared the microbiome pro-
files between the two habitats (feces and saliva) and between the
two populations, KI and HP. We then investigated the long-term
effects of the various antibiotics on the salivary and fecal micro-
biomes immediately after the treatment and 1, 2, 4, and 12months
post antibiotic exposure. Metagenome prediction tools were used
to identify the differentially affected functional groups in all sam-
ples. Furthermore, full metagenome sequencing on selected sam-
ples was carried out for the characterization of antibiotic resis-
tance gene (resistome) enrichment.
RESULTS
Of the 74 individuals included, 66 completed the study (Table 1).
In the KI study, all volunteers completed the study in the placebo
(n  10) and ciprofloxacin (n  10) groups, while 9 volunteers
remained in the clindamycin group. None of the volunteers expe-
rienced any side effects. In the HP study, of the 44 volunteers, 37
completed the study (13 in the placebo group, 14 in the amoxicil-
lin group, and 10 in the minocycline group). All dropouts (n 1
amoxicillin subject, n 5minocycline subjects, and n 1 placebo
subject)were lost to follow-up right after the baseline visit. Among
the subjects who completed the HP study, one individual in the
amoxicillin group presented with mild diarrhea and one pre-
sented with congestion following antibiotic treatment.
In total, 389 fecal and 391 saliva samples were analyzed by
sequencing part of the small subunit of the ribosomal gene (reads
available at the SRA of NCBI as SRP057504), yielding 6,825,563
reads after quality filtering with on average 8,751 (standard devi-
ation [SD], 2,601) reads per sample (minimum of 1,736 andmax-
imum of 22,253 reads). The reads were clustered into 1,972 oper-
ational taxonomic units (OTUs) at 97% similarity. To allow for
between-sample comparisons, the data were randomly sub-
sampled at 1,730 reads/sample.
Microbiome profiles. (i) Comparisons among baseline sam-
ples. First, the baseline samples from the two habitats—the oral
cavity (saliva) and the colon (feces)—were compared. The salivary
TABLE 1 Demographic and clinical data of study participants who finished the study, per study center and treatment group
Center Group n %males % Caucasian Avg age, yr (SD) Avg wt, kg (SD) Avg ht, cm (SD)
KI Placebo 10 50 100 26 (4) 74 (9) 179 (10)
Ciprofloxacin 10 50 80 26 (3) 69 (13) 176 (10)
Clindamycin 9 56 100 24 (5) 67 (11) 175 (9)
HP Placebo 13 31 69 30 (5) 78 (18) 171 (9)
Amoxicillin 14 29 79 27 (5) 74 (25) 175 (8)
Minocycline 10 30 90 22 (2) 67 (13) 171 (8)
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microbiomes formed distinct clusters away from the fecal micro-
biomes, and the oral habitats from both KI and HP overlapped in
the principal component analysis (PCA) (Fig. 1A). The fecal mi-
crobiomes were dichotomized by the second principal compo-
nent (PC2) into genus Prevotella- and genus Bacteroides-
dominated samples (Fig. 1A). Interestingly, the similarity among
the salivary microbiomes (average Bray-Curtis similarity, 0.61;
SD, 0.07) was significantly higher (P  0.001, Mann-Whitney
test) than that among the fecal samples (average Bray-Curtis sim-
ilarity, 0.44; SD, 0.08).
Second, we looked at each of the habitats separately and com-
pared the baseline samples from the two populations—the Swed-
ish (KI) versus the United Kingdom (HP) cohort. The first com-
ponent of the PCA on the fecal samples (Fig. 1B) separated
samples high in genus Prevotella proportion (four OTUs) on the
left side of the axis from the samples high in genusBacteroides (two
OTUs) and Alistipes and unclassified Bacteroidales (each a single
OTU) at the right side of the axis. Themajority of the sampleswere
dominated by the genus Bacteroides. The overall difference be-
tween the fecal microbiomes of the two centers was statistically
significant (P 0.0001, F 2.989, one-way permutational mul-
tivariate analysis of variance [PERMANOVA]) and was explained
by a higher abundance of OTUs belonging to the unclassified
Bacteroidales (1.16% of dissimilarity, similarity percentage
[SIMPER]) and Prevotella (1.1% of dissimilarity, SIMPER) in
the HP than in the KI data set and a higher abundance of an OTU
classified as Bacteroidales Ratan060301c (1% of dissimilarity,
SIMPER) in the KI samples.
Although salivary microbiomes showed a higher interindi-
vidual similarity than the fecal samples (Fig. 1A), salivary samples
clearly differed between the study populations (P  0.0001, F 
4.925, one-way PERMANOVA), where the second component of
the PCA, explaining 10% of the variance, determined this differ-
ence (Fig. 1C). The position of the samples (predominantly KI) in
the upper part of the plot was determined by six OTUs classified
into the genus Prevotella and one OTU classified as Porphyromo-
nas, while OTUs belonging to the genera Rothia and Streptococcus
determined the position of the samples (predominantly HP) in
the lower part of the plot.
(ii) Effects of antibiotics.Next,we addressed the effects of each
of the four antibiotics on the salivary and fecal microbiomes. A
microbial shift was observed in the KI study after both ciprofloxa-
cin and clindamycin exposure at week 1, month 1, andmonth 2 in
feces (Fig. 2A) but at only week 1 in saliva (Fig. 2B). In the HP
study, a minor shift in microbiome composition was observed in
feces at week 1 in the minocycline group (Fig. 2C), whereas saliva
showed no discernible pattern for microbial profile changes
(Fig. 2D).
The microbiome shifts were quantified using Bray-Curtis sim-
ilarity between the baseline sample and each of the other time
points within an individual subject. Exposure to clindamycin re-
sulted in the most pronounced and long-lasting change in micro-
bial profiles that remained statistically significant compared to the
placebo group for up to 4 months in the fecal samples (Fig. 3A)
and up to 1 month in saliva (Fig. 3B). The ciprofloxacin group
differed from the placebo group up to 1 month in feces (Fig. 3A).
In the HP study, feces from the minocycline group differed from
the placebo group up to 1 month (Fig. 3C). Finally, amoxicillin
treatment resulted in dissimilarity between baseline and week 1
samples compared to placebo group in both feces (Fig. 3C), and
saliva (Fig. 3D).
The fecal microbial diversity, expressed as a Shannon diversity
index, was clearly affected by each of the antibiotics—clindamy-
cin and ciprofloxacin—in the KI study. Compared to the baseline,
FIG 1 Comparison of baseline microbiome profiles from both types of sam-
ples, saliva and feces (A), and per sample type, feces (B) and saliva (C), by study
site, KI (Sweden) and HP (United Kingdom). The PCA plot is based on ran-
domly subsampled and log2-transformed OTU data. The data set included 37
saliva-feces baseline sample pairs from theHP study and 29 from the KI study.
The red ellipse highlights the two “types” of fecal samples—Prevotella- and
Bacteroides-dominated samples, respectively.
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the fecal microbiome diversity was significantly reduced for up to
4 months in the clindamycin group and even up to 12 months in
the ciprofloxacin group (see Fig. S1A in the supplemental mate-
rial). The salivarymicrobiome of the same groups showed a short-
term reduced diversity only immediately after the exposure to
ciprofloxacin (see Fig. S1B). Quite in contrast to the observation
in the KI group, in the HP study, the only significant reduction in
microbiome diversity in fecal (see Fig. S1C) and saliva (see
Fig. S1D) samples was observed directly after the exposure to mi-
nocycline. Exposure to amoxicillin had no significant effect on
microbiome diversity in either of the two habitats (see Fig. S1C
and D).
Next, we explored the effects of exposure to antibiotics on in-
dividual microbial taxa. At the OTU level, no OTUs contributed
significantly to differences between the samples exposed to anti-
biotics and their respective placebo (P  0.05, Welch’s t test,
Welch’s inverted confidence interval [CI] method, and Storey
false discovery rate [FDR] correction for multiple comparisons).
However, lowering the resolution to a higher taxonomic level (ge-
nus or higher) allowed identification of taxa that were affected by
antibiotics. For fecal samples, exposure to antibiotics resulted in
changes in the relative proportions of different genera or higher
taxa belonging to nearly all phyla (see Table S1 in the supplemen-
tal material). Only the phylum Verrucomicrobia with its sole rep-
resentative—genus Akkermansia—was not affected by any of the
antibiotics. In saliva, the effects were less pronounced, while some
phyla, such as Proteobacteria or candidate division TM7, were af-
fected by all or three of the four antibiotics, respectively (see Ta-
ble S2).
Predictive metagenomics. A computational approach
(PICRUSt) predicts the functional composition of a metagenome
using 16S rRNA gene data and a database of reference genomes
(23). We applied PICRUSt to our data and validated the outcome
with full metagenome data from selected salivary and fecal sam-
ples. Predictions based on 16S rRNA gene amplicon data showed
a high accuracy compared to the metagenomic shotgun sequenc-
ing from both saliva (average Spearman’s rho, 0.92; SD, 0.03) and
fecal (average Spearman’s rho, 0.86; SD, 0.03) samples.
(i) Comparison of baseline samples. Interpopulation ob-
served differences in the microbiome composition at baseline
(Fig. 1B and C) were confirmed by differences in the predicted
microbiome KEGG orthologous groups (KOs) (see Fig. S2 in the
supplemental material), where 1,021 from the predicted 4,737
KOs in feces and 2,119 from the 4,598 predicted KOs in saliva
differed significantly in their proportion between the KI and HP
populations (P  0.05, Welch’s t test, Welch’s inverted CI
method, and Storey FDR correction for multiple comparisons).
When the predicted metagenome data were summarized into
functional groups, the fecal baseline samples from KI displayed a
significantly higher proportion of bacterial genes encoding motil-
FIG 2 Effects of antibiotics on microbiome profiles of feces (A) and saliva (B) from the KI study and feces (C) and saliva (D) from the HP study. The PCA plot
is based on log2-transformed OTU data. Different colors indicate different time points; different symbols indicate different treatment groups. Outliers in the KI
(A) and HP (C) fecal data sets are highlighted with the respective subject number.
Zaura et al.
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ity proteins, ABC transporters, chemotaxis proteins, secretion sys-
tems, transcription factors, sporulation proteins, and flagellar as-
sembly proteins than did the samples fromHP (see Fig. S2C). The
HP fecal samples showed an increased abundance of genes linked
to ion channels, biosynthetic activity, and catabolism of different
molecules (see Fig. S2C). Among the significantly different KOs in
feces, 10 KOs were associated with antibiotic resistance and all but
one of these KOs were at a significantly higher proportion in HP
samples than in KI samples (see Table S3), suggesting a higher
antibiotic resistance gene load in theHPpopulation at the baseline
of the study. For saliva, a significantly higher proportion of func-
tional groups related to assimilative processes was found in the KI
group, while HP samples had a higher relative abundance of func-
tional groups related to dissimilation (see Fig. S2D). With respect
to antibiotic resistance in saliva, 16 of the significantly different
KOs between the two centers were associated with antibiotic re-
sistance—with each of the centers showing a higher proportion in
half of these KOs (see Table S3).
(ii) Effects of antibiotics.To assess the effects of antibiotics on
the predicted metagenomes, we compared KOs from the pre-
dicted metagenomes in the antibiotic groups with the predictions
from the respective placebo group. At baseline, no differences in
relative abundances of the KOs between any of the antibiotic
groups and the placebo group were observed. Exposure to antibi-
otics resulted in significantly different proportions of 4 to 14% of
the predicted KOs in fecal samples in all four antibiotic groups,
although at different time points. For instance, immediately after
clindamycin administration only three of 4,606 KOs significantly
differed in their proportion from the placebo group. This number
increased to 512 KOs (11% of all KOs) at 1 month after exposure
to clindamycin (Fig. 4A). In contrast, in amoxicillin-exposed fe-
ces, 706 of 4,968 KOs (14% of all KOs) were significantly different
at week 1 compared to baseline, while this significance was lost at
month 1. Although exposure to clindamycin had a strong impact
on feces, it did not result in significant changes in predicted pro-
portions of KOs in saliva (Fig. 4B). Among all saliva samples, only
FIG 3 Similarity inmicrobiome profiles between the baseline (BL) and the other visits (W1, week 1;M1,month 1;M2,month 2;M4,month 4;M12,month 12).
The horizontal bar indicates the mean value; the error bar indicates the 95% confidence interval. Bray-Curtis similarities were calculated between the log2-
transformedmicrobiome profiles of the baseline and each of the other time point samples of the respective individual. Brackets connect statistically significantly
different groups within each visit pair (P 0.05; one-way analysis of variance, Games-Howell post hoc test).
Ecological Impact of Antibiotics on Microbiome
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the predicted metagenomes of the samples collected immediately
after exposure to ciprofloxacin showed a significant effect, where
310 of 4,289 KOs (7% of KOs) differed from placebo group at
week 1 (see Fig. S3 in the supplemental material).
From the analysis of the predicted fecal metagenomes, it could
be concluded that 1 month after the exposure to clindamycin, 74
KOs were significantly increased compared to the placebo group,
and 438 KOs showed a significant decrease. Reduction in spore
formation and lactose-arabinose metabolism were among the
most affected functions (Fig. 5). At the same time, a decrease in the
fermentative butyrate-producing pathways was observed. Three
of the KOs that showed a significant increase in feces after expo-
sure to clindamycin were associated with antibiotic resistance (see
Table S4 in the supplemental material).
One month after exposure to ciprofloxacin, fecal sample met-
agenome predictions revealed 110 KOs that were significantly in-
creased in their proportion, with 502 KOs being decreased (see
Fig. S3 in the supplemental material). Among the most affected
KOs were two subunits of the pyruvate ferredoxin oxidoreduc-
tase—PorB and PorD—an observation in agreement with a de-
creased sporeformer community (see Fig. S4). Among the KOs
that increased in relative abundance after ciprofloxacin exposure
compared to placebo, one KO was associated with antibiotic re-
sistance (see Table S4). Among the KOs that decreased in propor-
tion after ciprofloxacin compared to placebo use were 4 KOs that
are associated with antibiotic resistance (see Table S4).
Exposure tominocycline resulted in 102 significantly increased
and 81 significantly decreased predicted KO proportions in fecal
samples immediately after exposure to antibiotics compared to
the placebo group. In general, KOs associated with respiratory
processes and amino acid synthesis were reduced and those asso-
ciated with amino acid degradation and nitrogen metabolism
FIG 4 Relative abundance of the predicted KEGG orthologous groups (KOs) in the fecal (A) and salivary (B) samples from the clindamycin group plotted
against the samples from the KI placebo group per individual time point. Error lines indicate standard deviations. No significant differences were observed in
saliva, while in feces, 3 KOs at 1 week post-antibiotic treatment and 512 of the 4,606 predicted KOs at 1 month post-antibiotic treatment were significantly
different in their proportions from the placebo group (P 0.005, Welch’s t test, Welch’s inverted confidence interval method, and Storey FDR correction for
multiple comparisons).
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were increased compared toKOs in the placebo group. It is tempt-
ing to interpret this observation as being the result of an increase
in amino acid abundance of the environment, possibly by lysis of
a nonidentified subpopulation. Three of the KOs with increased
proportions were associated with antibiotic resistance, while one
antibiotic-resistance-associated KO decreased in proportion (see
Table S4 in the supplemental material).
Exposure to amoxicillin resulted in 272 significantly increased
and 434 significantly decreased predicted KOs in feces immedi-
ately after the antibiotic exposure, compared to the placebo group.
Nine KOs associated with antibiotic resistance increased after
amoxicillin exposure, while four antibiotic-resistance-associated
KOs decreased in their proportion (see Table S4 in the supple-
mental material).
Full metagenome: presence of antibiotic resistance genes.
From each antibiotic group and each sample type, a baseline and a
postantibiotic sample were selected that showed the most pro-
nounced change in microbiome profile after exposure to antibi-
otics. In total, 18 samples were processed for full metagenomic
shotgun sequencing. We calculated fold changes in genes associ-
ated with antibiotic resistance types present in the Antibiotic Re-
sistance Genes Database (ARDB) (24) between the baseline and
post-antibiotic-treatment samples. At baseline, salivary samples
from the United Kingdom study (HP) had on average a 1.13-
times-higher load of antibiotic resistance genes than those from
the Swedish study (KI), while the loads in fecal samples from the
two countries were similar (HP/KI ratio  0.97). After exposure
to antibiotics, the antibiotic resistance gene load increased slightly
in feces (mean, 1.07; SD, 0.15), while it remained stable in saliva
(mean, 0.99; SD, 0.17).
Next, we calculated fold changes in antibiotic resistance genes
for individual sample pairs (see Table S5 in the supplemental ma-
terial). After administration of minocycline (a tetracycline),
erythromycin resistance (rRNA adenine N-6-methyltransferase,
Erm*) and especially efflux pumps (OprN, Tet*) increased in
abundance in both saliva and fecal samples (see Table S5). In
saliva, chloramphenicol acetyltransferase (CatB1) and a class A
beta-lactamase (BL2f_Sme1) also increased, while in feces resis-
tance to streptomycin (Str), efflux pumps (cml_e7, AdeC, and
EmrD), and resistance to aminoglycosides (Aac6Ie, Ant6Ia, and
EmrD) were present. The general pattern showed protection
against protein synthesis inhibitors (tetracycline, erythromycin,
streptomycin, and chloramphenicol).
After treatment with amoxicillin (a penicillin), a general pat-
tern of protection against antibiotics appeared, which included a
beta-lactamase (BL2), but also efflux pumps (Mex*, AmrA, and
OprN) and protection against erythromycin, aminoglycosides
(methyltransferases [Erm*] and aminoglycoside alteration
[Aac*]), and trimethoprim (group A drug-insensitive dihydrofo-
late reductase [Dfr*]). More beta-lactamases (BL*) were present
after treatment in feces than in saliva (see Table S5 in the supple-
mental material).
After exposure to ciprofloxacin (a fluoroquinolone), there
was no clearly related signal observed in saliva (see Table S5 in
the supplemental material). In feces, the response to cipro-
floxacin from two individuals (subjects 6 and 18) differed re-
garding beta-lactamases and efflux pumps (see Table S5), while
it was generally related to the same classes of antibiotics (ami-
noglycosides, beta-lactams, chloramphenicol, erythromycin,
and tetracyclines).
For clindamycin, shifts in the Erm methyltransferases (Erm*)
were very prominent in both saliva and feces (see Table S5 in the
FIG 5 Most significantly affectedKOs (26 of 520) in the predictedmetagenomes from clindamycin-exposed feces atmonth 1 compared to the respective placebo
group samples. FAD, flavin adenine dinucleotide; SEPHS, selenophosphate synthetase.
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supplemental material). In saliva, several efflux pumps, including
themacrolide-lincosamide-streptograminB efflux pump (LmrB),
appeared. In feces, aminoglycoside modification proteins (Aac*
and Aph*) and lincosamide nucleotidyltransferase (LnuA) were
more abundant.
In general, the most enhanced resistance genes were related to
antibiotics that work intracellularly, such as the Erm genes and the
tetracycline efflux and multidrug resistance efflux pumps.
DISCUSSION
Here, we reported that, depending on the type of antibiotics, the
effects of a single antibiotic exposure on the human gut micro-
biome can be very aggravating and prolonged, while ecological
consequences of the same exposure on the salivary microbiome
are short-lived and superficial. Additionally, based on metag-
enome predictions and the affected taxa, we can conclude that a
single use of antibiotic treatment, especially the lincosamide clin-
damycin and the quinolone ciprofloxacin, in a healthy population
may severely affect short-chain fatty acid (SCFA) production in
the gut.
Undesired effects of clindamycin consist of gastrointestinal
disturbances, the incidence varying between 2% and 20% (22).
Although members of the current study population did not pres-
ent with any clinically significant side effects, exposure to antibi-
otics had a significant effect on the gut ecosystem. A month after
the exposure to clindamycin, spore-forming, lactose-arabinose
metabolism, and fermentative butyrate-producing pathways were
among the most significantly reduced functions in the predicted
metagenomes. A month after ciprofloxacin use, a significant re-
duction in pyruvate metabolism was predicted. The SCFA bu-
tyrate is synthesized from complex polysaccharides via pyruvate
and the acetyl coenzyme A pathways (25). The reduction in the
predicted butyrate-producing pathways corresponded with a sig-
nificant decrease in Faecalibacterium, Subdoligranulum, uncul-
tured Ruminococcaceae, Roseburia, Coprococcus, and uncultured
Lachnospiraceae, known as butyrate producers (25). These obser-
vations suggest a specific and pronounced negative effect of clin-
damycin and ciprofloxacin on butyrate production in the gut.
Actual measurements of SCFAs in feces are suggested to be unre-
liable due to their fast uptake and metabolism in the colon by the
host and due to different intestinal transit times (26). Production
of butyrate has been associated with positive effects on gastroin-
testinal health by butyrate functioning as an energy source for
colonocytes and by inhibiting inflammation, carcinogenesis, and
oxidative stress in the gut (26).
The metagenome prediction data indicate that microbiome
functions recovered earlier than the microbial community
composition following exposure to antibiotics. This supports
the importance of functional redundancy within gut microbi-
ota, as suggested previously after a single exposure to cipro-
floxacin in three healthy adults (16). However, metagenome
predictions also showed that, even without significant effects of
antibiotics on microbiome composition, the functions or
KEGG orthologous groups might have been significantly af-
fected, as in the case with amoxicillin-exposed fecal samples.
The most likely explanation for this phenomenon is the indi-
vidualized response to this antibiotic at a taxonomic level,
meanwhile affecting similar general functionality in the differ-
ent microbial taxa.
The two study populations that participated in the project dif-
fered in their (baseline) microbiome composition. Since the fecal
microbiome is greatly shaped by diet (27), it would have been very
informative to compare the dietary habits of the two cohorts. Un-
fortunately, such information was not collected. Even more strik-
ing were the differences in the salivary microbiota: the predomi-
nant taxa in KI saliva samples were Prevotella spp., as opposed to
streptococci inHP samples. The tongue dorsum is shown to be the
main habitat for the anaerobic genus Prevotella (28, 29), while
streptococcal predominance can be related to either supragingival
plaque or nonkeratinized mucosa (28). Since no intraoral clinical
examination was performed during this study and the timing of
the last personal oral hygiene episode in respect to saliva collection
was not recorded, it is not possible to elucidate the exact reasons
for the observed differences.
Already prior to exposure to antibiotics in this study, both
study populations carried antibiotic resistance genes in their oral
and gut microbiomes. This is in line with the report on high levels
of antibiotic resistance gene carriage by salivary and fecal com-
mensal bacteria in two healthy individuals without prior exposure
to antibiotics for at least a year (30). Both metagenomic predic-
tions for 16S rRNAgene amplicon data and fullmetagenomic data
on selected samples indicated that theUnitedKingdom(HP) pop-
ulation had a higher antibiotic resistance gene load at the start of
the study. These differences may have affected the study out-
comes: a relatively weak effect of antibiotics on the gut and oral
microbiomes of theHP study population could be influenced by a
potentially higher carriage of antibiotic resistance genes at base-
line among the study volunteers from theUnited Kingdom. There
has been a significant decline in antibiotic use in Sweden in the last
2 decades, due to efforts put into the Swedish Strategic Pro-
gramme for theRationalUse of Antimicrobial Agents and Surveil-
lance of Resistance (STRAMA), which started in 1994 (31). Only
in 2013, after the end of the current study, was a similar initia-
tive—the English Surveillance Programme for Antimicrobial Uti-
lization andResistance (ESPAUR) (11)—developed in theUnited
Kingdom. The first ESPAUR report compared the United King-
dom antibiotic consumption rates between 2010 and 2013 and
demonstrated an increase in total use of antibiotics by 6%, with
the highest increase (32%) of prescriptions issued predominately
by dentists (11, 12). In 2012, there were 20.1 defined daily doses
(DDD) of antimicrobials for systemic use per 1,000 inhabitants
consumed in the United Kingdom outside hospitals (community
use) compared to 14.1 DDD in Sweden (12).
Exposure to different antibiotics resulted in an increased abun-
dance of genes associated with antibiotic resistance. Among the
antibiotics tested, exposure to amoxicillin resulted in the least dis-
cernible effects on themicrobiome composition, while these sam-
ples had the highest number with antibiotic resistance-associated
genes and the most classes that were increased in the predicted
metagenomes and in the full metagenomes, respectively, a week
after the exposure.
One of the mechanisms of resistance to clindamycin in-
volves acquisition of an erm gene (erythromycin ribosome
methylase) usually carried on plasmids or transposons in
pathogenic bacteria (19). Comparison of antimicrobial resis-
tance levels in strains isolated 30 years apart (1970s and 2000)
showed that Gram-negative Bacteroides species have acquired
an ermB gene that originated in Gram-positive bacteria—Clos-
tridium perfringens, Streptococcus pneumoniae, and Enterococ-
cus faecalis (32). Interestingly, our full metagenome samples
Zaura et al.
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from an individual exposed to clindamycin (KI subject S15)
showed an increase in eight erm genes in feces and two erm
genes in saliva. The fecal ermB gene counts of this individual
were increased 240-fold, suggesting potential involvement of
plasmids or transposons. Whole-genome sequencing of indi-
vidual strains has revealed that a large proportion of resistance
genes in these strains have not evolved within the strain but
rather have been acquired by lateral gene transfer, e.g., by plas-
mids, transposable elements, and integrons (33).
Currently, no other studies have simultaneously assessed ef-
fects of different antibiotics on both oral and fecalmicrobiomes in
healthy individuals. In this study, the same exposure to antibiotics
resulted in two radically different responses in these two niches of
the human body. The salivary microbiome showed unexpected
stability, while themicrobial ecology of feces was significantly dis-
turbed for up to several months, depending on the type of antibi-
otics administered. The reasons for these differences are unknown
and should be addressed. A potential explanation could be related
to the pharmacokinetics of the antibiotics. Another,more intrigu-
ing possibility is that the oral microbial ecosystem possesses a
higher intrinsic resilience toward stress, including recovery from
exposure to antibiotics. This ecosystem has to surmount multiple
daily perturbations such as oral hygiene measures, including ex-
posure to topical antimicrobial agents and physical removal by
tooth brushing, as well as alterations in temperature and oxygen
(34). None of this is applicable to the colon, where more subtle
effects, e.g., alterations in dietary habits, would bemore common.
A recent report did find changes in bacterial communities in both
saliva and feces after antibiotic use (35). The study populations
and study design, however, were highly different: the individuals
assessed byAbeles and coauthors (35) had amedical indication for
antibiotic use and received a prolonged (6-week) mixture of
broad-spectrum antibiotics, while we focused on healthy individ-
uals and a single antibiotic dose. Unfortunately, the authors did
not report the effects of antibiotics after the discontinuation of the
antibiotic use, precluding a comparison regarding the long-term
effects and potential differences in resilience between the two mi-
crobial ecosystems.
In conclusion, we have demonstrated that two European pop-
ulations differ in their salivary and fecal microbiome composi-
tions and in their antibiotic resistance gene prevalence. The sali-
vary microbiome was far less affected and more resilient toward
the exposure to antibiotics than the fecal microbial community in
these populations, irrespective of the antibiotic used. Two of the
antibiotics—clindamycin and ciprofloxacin—showed a severe
and long-term impact on the health-associated butyrate-
producing microbial community of the gut.
MATERIALS AND METHODS
Clinical study and 16S rRNA gene amplicon sequencing. This random-
ized clinical trial involved two research centers—The Karolinska Institute
in Sweden (KI) and Helperby Therapeutics Ltd. in the United Kingdom
(HP). Each study was approved by the respective institutional boards and
the respective national competent authorities and was registered with the
European Union Clinical Trials Register (for details, see Text S1 in the
supplemental material). Each center involved healthy volunteers, ran-
domized into two test groups and one control group. At KI, 30 volunteers
were randomly assigned to either the ciprofloxacin (Cipro), the clinda-
mycin (Clinda), or the placebo (Plac KI) group. AtHP, 44 volunteers were
randomly assigned to the amoxicillin (Amox, n  15), the minocycline
(Minoc, n 15), or the placebo (Plac HP, n 14) group. Saliva and fecal
sampleswere collected on 6 occasions: immediately before administration
of the antibiotic (baseline), immediately after the treatment course was
completed (week 1), and 1 month, 2 months, 4 months, and 12 months
postdosing. Sample DNA was extracted, 16S rRNA gene amplicons were
sequenced, and data were processed as described previously (36–38) (see
Text S1).
Metagenomic shotgun sequencing.Metagenomic libraries were pre-
pared from isolated DNA using the NEB DNAMastermix Library prepa-
ration kit (New England Biolabs), with size selection by eGel (Life Tech-
nologies). Libraries were sequenced for 250-bp paired-end reads using the
Illumina MiSeq reagent kit V2 on an Illumina MiSeq sequencer. After
quality filteringwith Trimmomatic (39), the paired and unpaired forward
reads were combined and reads with more than 10% ambiguous bases
were removed. Next, the reads were screened for human sequences with
Best Match Tagger v3.101 (K. Rotmistrovky and R. Agarwala, 2010), after
which human reads and duplicate reads were removed.
Metagenome prediction from 16S rRNA gene amplicon data and
validation with shotgun data. Microbial metagenomes were predicted
from 16S rRNA gene sequences using PICRUSt (23) according to the
pipeline at http://picrust.github.io/picrust/ (see Text S1 in the supple-
mental material).
Resistome analysis. Antibiotic resistance genes were downloaded
from the Antibiotic Resistance Genes Database (ARDB) (24). The
downloaded data set (ardbAnno1.0), containing 7,828 entries, was
made nonredundant first (3,002 nonredundant records), and UBLAST
from USEARCH v7.0.1090 (40) was used to map the reads to the
ARDB proteins (E value threshold of 10, postfiltered to include hits
with a maximum E value of 1E10 inclusive). The results were pro-
cessed with HUMAnN (41) to assign weights to the proteins. These
weights were then normalized by dividing by the total number of fil-
tered (nonhuman) reads and summarized per antibiotic resistance
type. Next, fold changes were calculated for all resistance types with a
baseline weight larger than 1E8.
Statistical analyses. Both alpha and beta diversity statistics on OTU
data and predicted metagenome data analyses were performed using
PAST software (42) and SPSS version 20.0 and STAMP software (43) (see
Text S1 in the supplemental material).
Sequencing data. Sequences of the small subunit of the ribosomal
gene of fecal and saliva samples are available at the SRA of NCBI as
SRP057504.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org/
lookup/suppl/doi:10.1128/mBio.01693-15/-/DCSupplemental.
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Figure S1, PDF file, 0.1 MB.
Figure S2, PDF file, 0.3 MB.
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Figure S4, PDF file, 0.1 MB.
Table S1, PDF file, 0.1 MB.
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